Jounce Therapeutics Secures $56,000,000 Series B Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=dd45100d-23d8-408a-bac9-6634621330cc - Date
4/23/2015 - Company Name
Jounce Therapeutics - Mailing Address
1030 Massachusetts Avenue Cambridge, MA 02138 USA - Company Description
Jounce Therapeutics is focused on the discovery and development of first-in-class cancer immunotherapies designed to work not by treating a patient’s tumor directly, but instead by harnessing the patient’s immune system to seek out and attack cancerous cells and tumors. - Website
http://www.jouncetx.com - Transaction Type
Venture Equity - Transaction Amount
$56,000,000 - Transaction Round
Series B - Proceeds Purposes
Proceeds from the financing will be used to advance Jounce’s pipeline of cancer immunotherapy programs, including moving its lead program directed at Inducible T cell Co-stimulator (ICOS) into clinical testing, as well as advancing a second program through IND-enabling studies. In addition, the investment will support expanded discovery of novel treatments aimed at tumors that may be less likely to respond to T cell checkpoint monotherapy, including therapies that target innate immune and stromal cells. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
